| Date Filed | Type | Description |
| 09/04/2020 |
GN
| Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate |
| 08/11/2020 |
GN
| Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study |
| 08/10/2020 |
GN
| Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update |
| 08/06/2020 |
GN
| Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer |
| 07/31/2020 |
GN
| Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares |
| 07/28/2020 |
GN
| Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock |
| 07/21/2020 |
GN
| Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19 |
| 07/01/2020 |
GN
| Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board |
| 06/05/2020 |
GN
| Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency |
| 05/21/2020 |
GN
| Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics |
| 05/08/2020 |
GN
| Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19) |
| 05/04/2020 |
GN
| Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020 |
| 04/16/2020 |
GN
| Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock |
| 04/15/2020 |
GN
| Arcturus Therapeutics Announces Proposed Public Offering of Common Stock |
| 04/13/2020 |
GN
| Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency |
| 04/09/2020 |
GN
| Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine |
| 03/27/2020 |
GN
| Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System |
| 03/04/2020 |
GN
| Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™ |
| 02/19/2020 |
GN
| Arcturus Therapeutics to Present at Two Investor Conferences in March |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/08/2020 |
GN
| Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer |
| 11/04/2019 |
GN
| Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th |
| 10/02/2019 |
GN
| Arcturus Therapeutics to Present at Three Upcoming Investor Conferences |
| 09/23/2019 |
GN
| Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors |
| 08/26/2019 |
GN
| Arcturus Therapeutics To Present at Two Investor Conferences in September |
| 08/07/2019 |
GN
| Arcturus to Report Corporate Overview and Financial Results on August 15 |
| 08/01/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 07/15/2019 |
GN
| Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D. |
| 06/27/2019 |
GN
| Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency |
| 06/21/2019 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/20/2019 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 18, 2019 ARCTURUS THERAPEUTICS HOLDINGS INC. Delaware 001-38942 32-0595345 10628 Science Center Drive, Suite 250 San Diego, California 92121 Registrant's telephone number, including area code: 900-2660 Arcturus Therapeutics Ltd. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d...",
"Registration Rights Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Equity Purchase Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Third Amendment, to Research Collaboration and License Agreement, as amended on October 17, 2017 and April 20, 2018, between the Company and Ultragenyx Pharmaceutical Inc",
"Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases" |
|
| 06/19/2019 |
GN
| Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases |
| 05/20/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/20/2019 |
GN
| Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics |
|